JP2022501074A5 - - Google Patents
Info
- Publication number
- JP2022501074A5 JP2022501074A5 JP2021542089A JP2021542089A JP2022501074A5 JP 2022501074 A5 JP2022501074 A5 JP 2022501074A5 JP 2021542089 A JP2021542089 A JP 2021542089A JP 2021542089 A JP2021542089 A JP 2021542089A JP 2022501074 A5 JP2022501074 A5 JP 2022501074A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- γδt
- sequence
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025085673A JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739822P | 2018-10-01 | 2018-10-01 | |
| US62/739,822 | 2018-10-01 | ||
| PCT/US2019/054132 WO2020072536A1 (en) | 2018-10-01 | 2019-10-01 | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085673A Division JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501074A JP2022501074A (ja) | 2022-01-06 |
| JP2022501074A5 true JP2022501074A5 (enExample) | 2022-10-12 |
| JP7687952B2 JP7687952B2 (ja) | 2025-06-03 |
Family
ID=68393055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210388100A1 (enExample) |
| EP (1) | EP3860645A1 (enExample) |
| JP (2) | JP7687952B2 (enExample) |
| KR (1) | KR20210070330A (enExample) |
| CN (1) | CN113056283A (enExample) |
| AU (1) | AU2019354391A1 (enExample) |
| BR (1) | BR112021006182A2 (enExample) |
| CA (1) | CA3115139A1 (enExample) |
| EA (1) | EA202190926A1 (enExample) |
| IL (1) | IL281922A (enExample) |
| MX (1) | MX2021003745A (enExample) |
| SG (1) | SG11202103235PA (enExample) |
| WO (1) | WO2020072536A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP4004049A1 (en) * | 2019-07-24 | 2022-06-01 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113667640B (zh) * | 2021-08-27 | 2022-09-02 | 广州百暨基因科技有限公司 | CAR-γδT细胞的制备方法 |
| WO2023102264A1 (en) * | 2021-12-05 | 2023-06-08 | Adicet Therapeutics, Inc. | Treatment of b cell malignancies |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| CN121419987A (zh) * | 2023-07-07 | 2026-01-27 | 南京传奇生物科技有限公司 | 蛋白质及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| AU2005336093B2 (en) | 2004-10-08 | 2011-02-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Adoptive immunotherapy with enhanced T lymphocyte survival |
| JP2008541758A (ja) * | 2005-06-02 | 2008-11-27 | アストラゼネカ エービー | Ｃｄ２０に対する抗体およびその使用 |
| MX2010000970A (es) * | 2007-07-31 | 2010-03-09 | Regeneron Pharma | Anticuerpos humanos contra cd20 humano y metodo para utilizarlos. |
| WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PT2710123T (pt) | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| HK1212240A1 (en) * | 2012-09-07 | 2016-06-10 | 吉宁特有限公司 | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| CN107058354A (zh) * | 2013-04-01 | 2017-08-18 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| EP3060059A4 (en) | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| CN107075480A (zh) | 2014-07-09 | 2017-08-18 | Tc生物制药有限公司 | γδT细胞及其用途 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| EP3189073B2 (en) * | 2014-09-04 | 2025-06-11 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| IL297773B2 (en) * | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| AU2016274633B2 (en) | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| SG11201803934YA (en) | 2015-11-11 | 2018-06-28 | Intrexon Corp | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| US11299708B2 (en) | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| WO2018085690A1 (en) * | 2016-11-04 | 2018-05-11 | Bluebird Bio, Inc. | Anti-bcma car t cell compositions |
| JP2019535262A (ja) * | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| WO2018133877A1 (zh) | 2017-01-23 | 2018-07-26 | 科济生物医药（上海）有限公司 | 靶向bcma的抗体及其应用 |
| SG10202107136XA (en) * | 2017-02-08 | 2021-07-29 | Agency Science Tech & Res | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same |
| GB2562774A (en) | 2017-05-25 | 2018-11-28 | Mcdonald Michael | Genetic construct |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| CA3112584A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
-
2019
- 2019-10-01 US US17/281,574 patent/US20210388100A1/en active Pending
- 2019-10-01 BR BR112021006182-7A patent/BR112021006182A2/pt unknown
- 2019-10-01 CN CN201980070384.5A patent/CN113056283A/zh active Pending
- 2019-10-01 WO PCT/US2019/054132 patent/WO2020072536A1/en not_active Ceased
- 2019-10-01 KR KR1020217012805A patent/KR20210070330A/ko active Pending
- 2019-10-01 MX MX2021003745A patent/MX2021003745A/es unknown
- 2019-10-01 EA EA202190926A patent/EA202190926A1/ru unknown
- 2019-10-01 AU AU2019354391A patent/AU2019354391A1/en active Pending
- 2019-10-01 SG SG11202103235PA patent/SG11202103235PA/en unknown
- 2019-10-01 JP JP2021542089A patent/JP7687952B2/ja active Active
- 2019-10-01 EP EP19795699.8A patent/EP3860645A1/en active Pending
- 2019-10-01 CA CA3115139A patent/CA3115139A1/en active Pending
-
2021
- 2021-03-31 IL IL281922A patent/IL281922A/en unknown
-
2025
- 2025-05-22 JP JP2025085673A patent/JP2025134707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501074A5 (enExample) | ||
| JP7336457B2 (ja) | 抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用 | |
| CN111655716B (zh) | 基于il-15的与il-7和il-21的融合体 | |
| JP7111855B2 (ja) | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 | |
| CN110382539B (zh) | 用于cd16a定向的nk细胞结合的串联双抗体 | |
| CN106536563B (zh) | 嵌合抗原受体 | |
| JP2022066290A5 (enExample) | ||
| TWI646107B (zh) | Ｂｃｍａ及ｃｄ３之結合分子 | |
| JP6644678B2 (ja) | Ｃｔｌａ−４およびｃｄ４０の両方に特異的に結合可能である二重特異性分子 | |
| RU2018147423A (ru) | Анти-PD-L1 и IL-2 цитокины | |
| JP2025134707A5 (enExample) | ||
| JP2018508215A (ja) | Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ） | |
| JP2020513819A (ja) | Ｃｔｌａ４抗体、医薬組成物およびその使用 | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| CN111386125A (zh) | 多肽 | |
| TW202221021A (zh) | 改良之抗原結合受體 | |
| JP2022513321A5 (enExample) | ||
| CN115232209A (zh) | 靶向gprc5d的抗体及其用途 | |
| JP2024525492A5 (enExample) | ||
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| TW201841944A (zh) | 4-1bbl變異體及包含其之融合蛋白 | |
| JP2022532249A (ja) | インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法 | |
| JP2024536840A (ja) | Ｉｌ－２バリアント及びその融合タンパク質 | |
| KR20210081346A (ko) | Nk 관여 분자 및 이의 사용 방법 | |
| KR20240046224A (ko) | 이중특이성 항체 및 그 용도 |